Quantcast

Latest Gonadotropin-releasing hormone Stories

2009-11-20 07:07:00

WHITEHOUSE STATION, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Merck & Co., Inc. today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended approval of ELONVA® (corifollitropin alfa injection) as a treatment in controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART) program....

2009-08-04 07:55:00

PARSIPPANY, N.J., Aug. 4 /PRNewswire/ -- Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved the trade name FIRMAGON(R) (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix. FIRMAGON is a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer. Since initial market introduction under the generic name degarelix,...

67e7656a315252d631540917b979c4ac1
2009-06-23 16:40:00

 University of California, Berkeley, researchers have found what they think is a critical and, until now, missing piece of the puzzle about how stress causes sexual dysfunction and infertility.Scientists know that stress boosts levels of stress hormones - glucocorticoids such as cortisol - that inhibit the body's main sex hormone, gonadotropin releasing hormone (GnRH), and subsequently suppresses sperm count, ovulation and sexual activity. The new research shows that stress also...

2009-06-16 15:10:00

SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that data from Phase I and Phase II elagolix trials and preclinical work was presented at the 91st Annual Meeting of the Endocrine Society (ENDO 09) in Washington DC, June 10-13, 2009. The first clinical abstract presentation at ENDO 09 reviews the results of a Phase I study in which elagolix was evaluated over six weeks (42 days) in 60 healthy premenopausal women. The study was a...

2009-06-01 06:00:00

QUEBEC CITY, June 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it presented results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108 (formerly AN-152), in prostate cancer. The presentation was made during yesterday's poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held through June 2,...

2008-12-24 16:52:00

New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth. PARSIPPANY, N.J., Dec. 24 /PRNewswire/ -- Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Potential trade names are still...

2008-12-18 12:48:00

SAINT PREX, Switzerland, December 18 /PRNewswire/ -- - New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-Term Suppression of Testosterone Ferring Pharmaceuticals received today notification that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), has adopted a positive opinion and is recommending to grant a marketing authorization for FIRMAGON(R) (degarelix), a new GnRH receptor antagonist...

2008-12-12 10:29:44

A team of scientists from the University of Cambridge and the University of Cukurova in Turkey have taken a major step to understanding how the brain controls the onset of puberty. The research, published in this week's Nature Genetics, identified the hormone Neurokinin B as a critical part of the control system that switches on the master regulator of human puberty. Although Neurokinin B was previously known to be present in the hypothalamus, the part of the brain that controls puberty, its...

2008-12-10 23:59:52

Treating prostate cancer patients by blocking hormonal activity does not appear to increase their risk of cardiovascular disease, U.S. researchers say. Researchers at the Massachusetts General Hospital said that since the male hormones -- androgens -- can accelerate the development of prostate cancer, reducing their activity is a standard part of treating the disease. GnRH agonist therapy is routinely administered to men whose cancer has spread beyond the prostate gland, and its use in...

2008-12-03 13:24:14

Degarelix avoids initial hormone surge seen in other drugsMore than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU International.They also experienced much greater falls in their prostate-specific antigen (PSA) levels at 14 and 28 days than men taking leuprolide.Researchers from Canada, the USA, France, Denmark and the Netherlands...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related